Published in Proc Natl Acad Sci U S A on August 06, 1996
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (2001) 4.22
Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol (1998) 2.34
Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A (1998) 2.11
Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci U S A (1997) 2.04
Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol (2003) 1.99
Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A (1998) 1.93
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol (2011) 1.92
Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer (2003) 1.61
Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.47
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia (1999) 1.47
Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am J Pathol (2000) 1.44
Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J (2000) 1.43
Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol (2003) 1.39
Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med (1997) 1.39
Steady-state analysis of genetic regulatory networks modelled by probabilistic boolean networks. Comp Funct Genomics (2003) 1.39
Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol (1998) 1.31
Establishing a link between oncogenes and tumor angiogenesis. Mol Med (1998) 1.29
Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am J Pathol (2007) 1.12
Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer (2009) 1.09
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs (2010) 1.09
An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration. Proc Natl Acad Sci U S A (2001) 1.07
Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy. World J Gastroenterol (2001) 1.07
AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer (2001) 1.01
VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma. World J Gastroenterol (2002) 1.01
Glioma morphology and tumor-induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography. J Magn Reson Imaging (2010) 1.00
Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. Br J Radiol (2011) 1.00
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol (2010) 0.99
Antiangiogenic therapy in brain tumors. Expert Rev Neurother (2008) 0.95
Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Invest (2014) 0.93
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis. Oncogene (2010) 0.92
In vivo characterization of several rodent glioma models by 1H MRS. NMR Biomed (2011) 0.92
Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma. Aging (Albany NY) (2010) 0.89
Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection. J Virol (2004) 0.89
Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes. Mol Cancer Res (2012) 0.88
Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer (2002) 0.87
MicroRNA in Human Glioma. Cancers (Basel) (2013) 0.87
Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. Mol Pathol (1997) 0.87
Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro. Br J Cancer (2002) 0.86
Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer (2001) 0.85
Carboxymethyl benzylamide dextran inhibits angiogenesis and growth of VEGF-overexpressing human epidermoid carcinoma xenograft in nude mice. Br J Cancer (2003) 0.82
Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy. J Cell Mol Med (2007) 0.80
VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol (2008) 0.79
Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. Neuro Oncol (2016) 0.79
Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice. Clin Exp Metastasis (1999) 0.78
Aiding and ABT'ing Treatment for Glioblastoma. Cancer Biol Ther (2007) 0.77
Inhibitory effect of antisense vascular endothelial growth factor 165 eukaryotic expression vector on proliferation of hepatocellular carcinoma cells. World J Gastroenterol (2004) 0.75
Bevacizumab for glioblastoma: current indications, surgical implications, and future directions. Neurosurg Focus (2014) 0.75
Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy. PLoS One (2017) 0.75
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (1995) 9.84
Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 9.73
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (1989) 8.10
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell (1993) 7.14
Tumor angiogenesis. Adv Cancer Res (1985) 5.66
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 5.54
Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev (1992) 5.50
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (1994) 5.19
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem (1994) 4.41
Macrophages and angiogenesis. J Leukoc Biol (1994) 3.85
Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science (1985) 3.71
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol (1989) 3.62
Regulators of angiogenesis. Annu Rev Physiol (1991) 3.27
JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol (1990) 3.10
Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst (1972) 2.52
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst (1995) 2.07
Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B. Science (1992) 1.85
Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet (1994) 1.66
Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res (1996) 1.64
Angiogenesis in malignant gliomas. Glia (1995) 1.62
Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J Cell Biochem (1991) 1.45
Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest (1993) 1.42
Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res (1994) 1.30
Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat (1995) 1.26
Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res (1991) 1.20
Angiogenic growth factors in neural embryogenesis and neoplasia. Am J Pathol (1995) 0.96
Effects of antisense glial fibrillary acidic protein complementary DNA on the growth, invasion, and adhesion of human astrocytoma cells. Cancer Res (1994) 0.96
Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant. Mol Cell Biol (1993) 0.89
Genetics of cancer predisposition and progression. Clin Investig (1993) 0.81
SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell (1988) 12.69
Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature (1983) 11.57
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell (1985) 10.13
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A (1999) 7.70
Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78
The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell (1989) 6.43
The genome of the sea urchin Strongylocentrotus purpuratus. Science (2006) 6.41
ZnO nanowire UV photodetectors with high internal gain. Nano Lett (2007) 6.06
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell (1998) 5.92
Jak2 is essential for signaling through a variety of cytokine receptors. Cell (1998) 5.92
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
High-speed mapping of synaptic connectivity using photostimulation in Channelrhodopsin-2 transgenic mice. Proc Natl Acad Sci U S A (2007) 5.42
Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. Nat Genet (1999) 4.79
Noncovalent sidewall functionalization of single-walled carbon nanotubes for protein immobilization. J Am Chem Soc (2001) 4.46
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ (2006) 3.95
SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell (1989) 3.88
Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med (1999) 3.72
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol (1986) 3.65
Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity (1999) 3.53
Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A (1997) 3.48
Loss of alleles at loci on human chromosome 11 during genesis of Wilms' tumour. Nature (1984) 3.37
Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res (2000) 3.24
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res (1991) 3.16
SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell (1999) 3.15
The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res (1998) 3.15
A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res (1996) 3.00
Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature (1985) 2.96
Flow of mitochondrial DNA across a species boundary. Proc Natl Acad Sci U S A (1983) 2.91
A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron (1999) 2.82
In vitro studies of piperacilin, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.82
Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology (2008) 2.79
Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics (1998) 2.79
Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation (1996) 2.77
Ecology. Giant pandas in a changing landscape. Science (2001) 2.73
Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J Biol Chem (2000) 2.70
Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest (1998) 2.65
Membrane flow and differentiation: origin of Golgi apparatus membranes from endoplasmic reticulum. Adv Cytopharmacol (1974) 2.58
Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet (1989) 2.56
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J Med Chem (1994) 2.47
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med (1995) 2.47
Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A (1985) 2.44
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell (2000) 2.41
Clonal genomic alterations in glioma malignancy stages. Cancer Res (1988) 2.39
Self-rated health and survival: a 7-year follow-up study of Australian elderly. Am J Public Health (1994) 2.37
Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol (1999) 2.34
The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci (2000) 2.28
Role of the alpha2-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor. J Biol Chem (1998) 2.26
Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials (2000) 2.24
Genetic origin of mutations predisposing to retinoblastoma. Science (1985) 2.22
SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell (1999) 2.19
Supersensitivity to allosteric GABA(A) receptor modulators and alcohol in mice lacking PKCepsilon. Nat Neurosci (1999) 2.17
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res (1999) 2.17
A mouse model of orthotopic vascularized aerated lung transplantation. Am J Transplant (2007) 2.16
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A (1998) 2.15
Quantum-state controlled chemical reactions of ultracold potassium-rubidium molecules. Science (2010) 2.15
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry (1996) 2.14
Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature (1987) 2.14
Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci U S A (1989) 2.14
Molecular cloning of Ly-1, a membrane glycoprotein of mouse T lymphocytes and a subset of B cells: molecular homology to its human counterpart Leu-1/T1 (CD5). Proc Natl Acad Sci U S A (1987) 2.13
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Integrin alpha8beta1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis. Cell (1997) 2.09
Human neutrophil activation and increased adhesion by various resuscitation fluids. Crit Care Med (2000) 2.09
A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE). Health Technol Assess (2013) 2.09
Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J Virol (2001) 2.08
Six mouse alpha-tubulin mRNAs encode five distinct isotypes: testis-specific expression of two sister genes. Mol Cell Biol (1986) 2.07
Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci U S A (1997) 2.04
Umbilical cord mesenchymal stem cell transplantation in drug-induced Stevens-Johnson syndrome. J Eur Acad Dermatol Venereol (2012) 2.03
Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A (1990) 2.03
A prospective study of surgeon-performed ultrasound as the primary adjuvant modality for injured patient assessment. J Trauma (1995) 2.01
Prevalence of antibodies to the hepatitis E virus in pigs from countries where hepatitis E is common or is rare in the human population. J Med Virol (1999) 2.01
Attributable causes of cancer in China. Ann Oncol (2012) 1.98
Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1. Nature (1986) 1.98
The mammalian beta-tubulin repertoire: hematopoietic expression of a novel, heterologous beta-tubulin isotype. J Cell Biol (1986) 1.97
Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor. J Immunol (1987) 1.97
Suppression of HIV infection in AZT-treated SCID-hu mice. Science (1990) 1.97
Identification and characterization of members of the FKHR (FOX O) subclass of winged-helix transcription factors in the mouse. Mamm Genome (2001) 1.94
GreA-induced transcript cleavage in transcription complexes containing Escherichia coli RNA polymerase is controlled by multiple factors, including nascent transcript location and structure. J Biol Chem (1994) 1.92
Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. J Biol Chem (1999) 1.91
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology (1997) 1.86
Increased NAD(P)H oxidase and reactive oxygen species in coronary arteries after balloon injury. Arterioscler Thromb Vasc Biol (2001) 1.86
Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Mol Cell Biol (1996) 1.86
Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11. Nature (1988) 1.84
Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res (1994) 1.84
Cell-specific transcriptional regulation of follicle-stimulating hormone-beta by activin and gonadotropin-releasing hormone in the LbetaT2 pituitary gonadotrope cell model. Endocrinology (2001) 1.82
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res (2000) 1.81